

Jonathan Bennett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7259096/publications.pdf>

Version: 2024-02-01

12
papers

1,256
citations

933447

10
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

2342
citing authors

#	ARTICLE	IF	CITATIONS
1	The promise and peril of chemical probes. <i>Nature Chemical Biology</i> , 2015, 11, 536-541.	8.0	698
2	An orally available non-nucleotide STING agonist with antitumor activity. <i>Science</i> , 2020, 369, .	12.6	282
3	A kinase-cGAS cascade to synthesize a therapeutic STING activator. <i>Nature</i> , 2022, 603, 439-444.	27.8	58
4	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5675-5689.	6.4	46
5	Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1548-1554.	2.8	44
6	Discovery of Amino-cyclobutane-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1530-1536.	2.8	38
7	Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1). <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 550-557.	2.8	28
8	Discovery of a chemical probe for PRDM9. <i>Nature Communications</i> , 2019, 10, 5759.	12.8	24
9	Carbamate and <i>N</i> -Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 389-396.	2.8	14
10	Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization. <i>Pharmaceuticals</i> , 2014, 7, 207-219.	3.8	11
11	Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1435-1440.	2.8	7
12	STimulator of INTERferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 282-293.	4.1	6